Investigational drug · Phase 3
Apatinib
Also called: RIVO, Rivoceranib
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, HCC, Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
584
Any phase or sponsor naming "Apatinib"
First trial start
2020
Sep 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Apatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- HCC
- Hepatocellular Carcinoma
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- Hepatocellular Carcinoma (HCC)
- Gastroesophageal Junction Cancer
- Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
- Malignant Neoplasms of Digestive Organs
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Apatinib" as an intervention, largest first.
Peking Union Medical College HospitalAcademic, hospital or other
NCT03892577 · 3,000 participants (planned) · Start Jul 1, 2017 · Primary completion Oct 1, 2023
Drug: Precision oncology including targeted therapy and immunotherapy · For: Objective Response Rate; Progression-free Survival; Overall Survival and 4 more
Sites: Beijing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT02426034 · 2,004 participants · Start May 15, 2015 · Primary completion May 29, 2020
Drug: ApatinibTablets · For: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Nanjing, China; Shanghai, China
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruiting
Xuhua DuanAcademic, hospital or other
NCT07156617 · 2,000 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 1, 2027
Drug: Systemic therapy · For: Hepatocellular Carcinoma (HCC)
Sites: Haikou, China; Xingtai, China; Dengzhou, China · 14 sites in all
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompleted
Zhongda HospitalAcademic, hospital or other
NCT05332821 · 1,244 participants · Start Dec 28, 2022 · Primary completion Jul 30, 2023
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab · For: Hepatocellular Carcinoma
Sites: Nanjing, China; Shanghai, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT04947956 · 1,000 participants (planned) · Start Sep 1, 2021 · Primary completion Sep 1, 2023
Drug: Camrelizumab · For: Unresectable Hepatocellular Carcinoma
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07645209 · 1,000 participants (planned) · Start May 13, 2026 · Primary completion May 13, 2028
Drug: Immune Checkpoint Inhibitors · For: Liver Cancer
Sites: Harbin, China
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompleted
Zhongda HospitalAcademic, hospital or other
NCT05332496 · 941 participants · Start Dec 28, 2022 · Primary completion Jul 30, 2023
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab · For: Hepatocellular Carcinoma
Sites: Nanjing, China · 2 sites in all
- A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast CancerPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT05889871 · 916 participants (planned) · Start Jun 1, 2023 · Primary completion Jun 1, 2026
Drug: Standard endocrine therapy plus Apatinib · For: HR+/HER2-breast Cancer
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03813784 · 885 participants · Start Mar 7, 2019 · Primary completion Jun 7, 2023
Drug: SHR-1210; Capecitabine and 2 more · For: Gastric Cancer; GastroEsophageal Cancer
Sites: Beijing, China
- Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04203485 · 762 participants (planned) · Start Jun 15, 2020 · Primary completion Mar 31, 2022
Drug: Camrelizumab 200mg; Apatinib Mesylate 250mg and 3 more · For: PD-L1 Positive Non-small Cell Lung Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Apatinib attenuates CRKII-Mediated angiogenesis: Possible implications for metastasis prevention from small extracellular vesicle proteomics.
Wei S, Mei Y, Liu C, et al. · Biochem Pharmacol 2026
- A Phase II Trial of Chemotherapy-Free Neoadjuvant Camrelizumab plus Apatinib for Resectable HNSCC: Pathologic Response and Vascular-Immune Cross-talk.
Jie Y, Chen Z, Chen L, et al. · Clin Cancer Res 2026
- A ketogenic enzyme HMGCS2 drives malignant progression in HER2-negative breast cancer via RAB23-mediated β-catenin/TCF signaling and mediates Apatinib resistance.
Wu J, Liu M, Li W, et al. · Life Sci 2026
- Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study.
Liu Z, Zhong J, Wan R, et al. · Cancers (Basel) 2026
- Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.
Zhong SS, Yu Y, Zhong XH, et al. · Drug Des Devel Ther 2026
- Combination of vinorelbine capsules and the small molecule anti-angiogenic drug apatinib for first-line treatment of advanced triple-negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report.
Bai X, Chen L, Chen X, et al. · Oncol Lett 2026
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.